ÉÂÍý³Ø­¶ / ¤·ì´ï


ÉÂÍý³Ø­¶

£±¡¥¡Ê1¡ËWHOʬÎà¤Ë¤ª¤¤¤Æ¹ü¿ñÁý¿£¾É¸õ·²¤Ë´Þ¤Þ¤ì¤ë¼À´µÌ¾¤Î¤¦¤Á¡¢ÂåɽŪ¤Ê4¤Ä¤òµ­ºÜ¤·¤Ê¤µ¤¤¡£
¡Ê2¡ËÉÂÍýÁÈ¿¥³ØŪ´Ñ»¡¤Ç¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¤È¿ÇÃǤ¹¤ë¤¿¤á¤ËɬÍפȤʤëÄ귿Ū¤ÊReed-SternbergºÙ˦¤ò¤ï¤«¤ê¤ä¤¹¤¯¿Þ¼¨¤·¡¢¤½¤Î·ÁÂÖ³ØŪ¤ÊÆÃħ¤ò¤¹¤Ù¤Æµ­ºÜ¤·¤Ê¤µ¤¤¡£

¡Ê2005ǯÉÂÍý³Ø¡¡¾®¥Æ¥¹¥È£²¡Ý£±¡Ë

²òÅú£±¡¢¹ü¿ñÁý¿£¾É¸õ·²¡áËýÀ­¹ü¿ñÁý¿£À­¼À´µ¡Ê¥í¥Ó¥ó¥¹ÉÂÍý³Ø¡Ë

£±¡¢ËýÀ­¹ü¿ñÀ­Çò·ìÉÂ
¡¡¤¹¤Ù¤Æ¤Î¾ÉÎã¤ÇPh(Philadelphia)À÷¿§ÂΤȤ¤¤¦ÆÈÆäÊÀ÷¿§Âΰ۾ï¤Ë´ØÏ¢¤¬¤¢¤ë¡£¤³¤ì¤Ï¡¢Ä̾ïÂè22ÈÖÀ÷¿§ÂΤÎĹÏÓ¤¬¡¢Âè9ÈÖÀ÷¿§ÂΤÎĹÏÓ¤ËÁê¸ßžºÂ¤·¤¿¤â¤Î¡£CML¤ÎºÙ˦µ¯¸»¤Ï¿ÀøǽÀ­´´ºÙ˦¤Ç¤¢¤ë¡£¤¹¤Ù¤Æ¤ÎCML¤Ç¤Ï¡¢BCR¡ÝABL¤Î¥­¥á¥é°äÅÁ»Ò¤ÏBCR¤ÎÉôʬ¤ÈABL¤Î¥Á¥í¥·¥ó¥­¥Ê¡¼¥¼¤ÎÎΰ褫¤é¹½À®¤µ¤ì¤ëÍ»¹ç¤¿¤ó¤Ñ¤¯¼Á¤ò¥³¡¼¥É¤¹¤ë¡£¤³¤ÎÍ»¹ç¤¿¤ó¤Ñ¤¯¼Á¤ÏÍÞÀ©¤¬¸ú¤«¤Ê¤¤¥Á¥í¥·¥ó¥­¥Ê¡¼¥¼³èÀ­Áý¶¯¤ò¤â¤¿¤é¤¹¡£
£²¡¢¿¿À­Â¿·ì¾É
¡¡Ã±°ì¤Î¼ðáçÀ­´´ºÙ˦ͳÍè¤ÎÀÖ·ìµå·Ï¡¢ðùγµå·Ï¡¢µð³Ëµå·Ï¤Î¤¹¤Ù¤Æ¤Î²á¾êÁý¿£¤¬¸«¤é¤ì¤ë¡£¿¿À­Â¿·ì¾É¤Ï·ìÀ¶Ãæ¤Î¥¨¥ê¥¹¥í¥Ý¥¨¥Á¥óÃͤÏÄãÃͤǡ¢ÀÖ·ìµå·Ï´ÎºÙ˦¤Î¼ðáçÀ­Áý¿£¤Ï¥¨¥ê¥¹¥í¥Ý¥¨¥Á¥ó¤ËÈó°Í¸À­¤Ç¤¢¤ë¡£ ¡¡·ÁÂÖ³ØŪÆÃħ ¡¡ÀÖ·ìµåÁý¿¾É¤Ë¤è¤ë·ì±ÕÎ̤ÎÁý²Ã¤È·ì±ÕÇ´Ä´Å٤ξ徺¡¢·ìήÄäÂڤηë²Ì¡¢·ìÀò¤ä¹¼ºÉ¤¬À¸¤¸¤ä¤¹¤¯¤Ê¤ê¡¢¤³¤ì¤é¤Ï¡¢¿´¡¢ç£Â¡¤ª¤è¤Ó¿Õ¤Ë¤â¿¤¯½Ð·ì¤¬¸«¤é¤ì¤ë¡£
£³¡¢¹ü¿ñÀþ°Ý¾É¤òȼ¤¦¹ü¿ñ²½À¸
¡¡ÁÈ¿¥³ØŪÊѲ½¡¦¡¦¡¦¿ñ³°Â¤·ìÁã¤Î¼ç¤ÊÉô°Ì¤Ïç£Â¡¤Ç¤¢¤ë¡£Ä̾ï¹âÅ٤˼ðÂ礷¡¢»þ¤Ë¤Ï£´£°£°£°g¤Ë㤹¤ë¡£ÀµÀÖ²êµå¡¢ðùγµå·ÏÁ°¶îºÙ˦¡¢¤ª¤è¤Óµð³Ëµå¤Î»°·ÏÅýºÙ˦¤ÎÁý¿£¤¬¤¢¤ë¡£¤·¤«¤·¡¢¿ô¤¬Áý²Ã¤·¤Æ´ñ²ø¤Ê·ÁÂÖ¤ò¼¨¤¹µð³Ëµå¤¬ÌÜΩ¤Ä¤³¤È¤¬Â¿¤¤¡£ ¡¡´Î¤ÏÃæÅùÅ٤˼ðÂ礷¡¢¿ñ³°Â¤·ìÁ㤬¸«¤é¤ì¤ë¡£ÁÈ¿¥³ØŪ¤Ë¡¢¥ê¥ó¥ÑÀá¤Ë¤â¿ñ³°Â¤·ìÁ㤬¸«¤é¤ì¤ë¤¬¡¢¤½¤ì¤Ï¼ðÂç¤ò¤­¤¿¤¹¤Û¤É¤Ë¤Ï¤Ê¤é¤Ê¤¤¡£

¡Ê°Ê¾å¡¢¥í¥Ó¥ó¥¹ÉÂÍý³Ø£ð¡¢£µ£µ£²¤«¤é¡Ë

£´¡¢ËÜÂÖÀ­·ì¾®ÈÄ·ì¾É¡Ê¥·¥ó¥×¥ëÉÂÍý³Ø£ð¡¢£²£²£¸¡Ë
¡¡¹ü¿ñÀ­Â¤·ì´´ºÙ˦¥ì¥Ù¥ë¤Î°Û¾ï¤Ë¤è¤ë¼ðáçÀ­Áý¿£À­¼À´µ¤Ç¡¢Ãø¤·¤¤·ì¾®ÈÄÁý²Ã¡Ê60Ëü/ ul °Û¾ï¡Ë¤òÆÃħ¤È¤¹¤ë¡£¹âÎð¼Ô¤Ë¹¥È¯¤·¡¢½Ð·ì¾É¾õ¡Ê»çÈá¢É¡½Ð·ì¡Ë¡¢·ìÀò¾É¾õ¡Ê¿¼ºßÀ­ÀÅÌ®·ìÀò¡¢Ç¾¹¼ºÉ¡¢¿´¶Ú¹¼ºÉ¡Ë¡¢ç£¼ð¤Ê¤É¤ÎÎ×¾²¾É¾õ¤òǧ¤á¤ë¤³¤È¤¬Â¿¤¤¡£
  • µÞÀ­Çò·ìɤÏʬ²½¤Î°Û¾ï¤Ç¤¢¤ë¡£¤¹¤Ê¤ï¤Á¡¢Íļã¤ÊÇò·ìɺÙ˦¤¬À®½Ï¤Ç¤­¤º¡¢Íļã¤ÊºÙ˦¤¬¹ü¿ñ¤ÎÂçȾ¤òÀê¤á¤ë¡£
  • ¤½¤ì¤ËÂФ·¡¢ËýÀ­Çò·ìɤÏÁý¿£¤Î°Û¾ï¤Ç¤¢¤ë¡£¤¹¤Ê¤ï¤Á¡¢Çò·ìɺÙ˦¤¬½½Ê¬¤ÊÀ®½Ïǽ¤ò»ý¤Á¡¢¹ü¿ñ¤Ï¼ï¡¹¤ÎÀ®½ÏÃʳ¬¤ÎÇò·ìɺÙ˦¤ÇÀê¤á¤é¤ì¤Æ¤¤¤ë¡£

¡Ê£²¡Ë¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¤ÎÉÂÍýÁÈ¿¥³ØŪÆÃħ¤Ï¡¢Reed SternbergºÙ˦¡ÊRSºÙ˦¡Ë¤¬´Ñ»¡¤µ¤ì¤ë¤³¤È¤Ç¤¢¤ë¡£ RSºÙ˦¤Ï¤È¤ê¤ï¤±ÆÃħŪ¤Ê¤Î¤Ï¡¢Æó¤Ä¤Î³Ë¤¬¶ÀÁü¤Î¤è¤¦¤Ëʻ¸¤·¡¢¤ª¤Î¤ª¤Î¤¬Âç·¿¡ÊÉõÆþÂÎÍ͡ˤι¥»ÀÀ­³Ë¾®ÂΤòÍ­¤·¡¢¤½¤Î¼þ°Ï¤ÏÆÈÆäÊÌÀÚô¡Êhalo¡Ë¤Ç°Ï¤Þ¤ì¤Æ¤ª¤ê¡¢¤Õ¤¯¤í¤¦¤ÎÌܤΤ褦¤Ë¸«¤¨¤ë¤³¤È¤Ç¤¢¤ë¡£³ËËì¤ÏÌÀÎƤǤ¢¤ë¡£

£¹¡Ë¡Ê1¡Ët(8¡¨14)(q24¡¨q32)¤È¤¤¤¦À÷¿§ÂΞºÂÍͼ°¤ÇÂåɽ¤µ¤ì¤ë°­À­¥ê¥ó¥Ñ¼ð¤Î°¡·¿¤Ë¤Ä¤¤¤Æ¡¤³ÆÀßÌä¤ËÅú¤¨¤Ê¤µ¤¤¡¥
¡Êa¡Ë¤³¤Î°¡·¿¤Î̾¾Î¡¢µÚ¤Óphenotype¾å¤ÎÆÃħ¤ò½Ò¤Ù¤è¡£
¡Êb¡Ë¤³¤Î°¡·¿¤Ë¤ª¤¤¤Æ¡¢8q24Éô°Ì¤Ë¸ºß¤·¤Æ¾åµ­¤ÎžºÂ¤Ë´Ø¤ï¤Ã¤Æ¤¤¤ë°äÅÁ»Ò¤Î̾¾Î¤Ï²¿¤«¡£
¡Êc¡Ë¤½¤Î8q24Éô°Ì¤ÎžºÂÁê¼ê¤Î°äÅÁ»Ò¤Î̾¾Î¤Ï²¿¤«¡£
¡Ê2¡ËWHO¤Ë¤è¤ëµÞÀ­¹ü¿ñÀ­Çò·ìÉÂʬÎà¡Ê2001ǯ¡Ë¤Ë¤Ä¤¤¤Æ³ÆÀßÌä¤ËÅú¤¨¤Ê¤µ¤¤¡£
¡Êa¡Ëͽ¸å¤¬ºÇ¤âÎɹ¥¤Ê·¿¤ÎÀ÷¿§Âΰ۾ï¤Ë¤Ä¤¤¤Æ¡¢À÷¿§ÂÎÈÖ¹æ¤ÈÀÚÃÇÉô°Ì¤òɽµ­µ¬Â§¤Ë½¾¤Ã¤Æµ­ºÜ¤·¤Ê¤µ¤¤¡£
¡Êb¡Ë¸Ç·Á¼ðáî¤ò·ÁÀ®¤·¤ä¤¹¤¤·¿¤ÎÀ÷¿§Âΰ۾ï¤Ë¤Ä¤¤¤Æ¡¢À÷¿§ÂÎÈÖ¹æ¤ÈÀÚÃÇÉô°Ì¤òɽµ­µ¬Â§¤Ë½¾¤Ã¤Æµ­ºÜ¤·¤Ê¤µ¤¤¡£
¡Êc¡Ë¡ÖAML with t(15;17)(q22;q11)¡×¤Èɽµ­¤µ¤ì¤Æ¤¤¤ë¼À´µÌ¾¤ò¡¢±Ñʸ¤Þ¤¿¤ÏÆüËܸìɽµ­¤Î¤¤¤º¤ì¤«¤Çµ­ºÜ¤·¤Ê¤µ¤¤¡£

¡Ê£²£°£°£´Ç¯ÉÂÍý³Ø¾®¥Æ¥¹¥È¡¡£¹¡Ë

²òÅú¡Ê£±¡Ë

(a)
¡¦¡¦¡¦phenotype = immunophenotype ÌȱֳØŪɽ¸½·¿¤Î¤³¤È¡£t(8;14)(q24;q32)¤Ï¥Ð¡¼¥­¥Ã¥È¥ê¥ó¥Ñ¼ðBurkit Lymphoma ¤Ç¤¢¤ë¡£ÌȱֳØŪɽ¸½·¿¤Ï¡¢¡ÖËܼðáç¤ÏBºÙ˦À­¤Ç¤¢¤ê¡¢ºÙ˦ɽÌ̤ÏIgM¡¢CD19¤Î¤è¤¦¤ÊÈÆBºÙ˦¥Þ¡¼¥«¡¼¡¢¤Þ¤¿¡¢CD£±£°¹³¸¶¤¬ÍÛÀ­¤Ç¤¢¤ë¡£¡×¡Ê¥í¥Ó¥ó¥¹P,£µ£³£¸¡Ë
(b)
¡¦¡¦¡¦MYC
(c)
¡¦¡¦¡¦IgH°äÅÁ»Ò

¡Ö¥Ð¡¼¥­¥Ã¥È¥ê¥ó¥Ñ¼ð¤ÏÂè8À÷¿§Âξå¤ÎMYC°äÅÁ»Ò¤ò´¬¤­¹þ¤àžºÂ¤È¶¯¤¤´ØÏ¢¤¬¤¢¤ë¡£¤Û¤È¤ó¤É¤ÎžºÂ¤ÏMYC¤ÈÂè14À÷¿§Âξå¤ÎIgH°äÅÁ»Ò¤È¤¬Í»¹ç¤¹¤ë¤â¤Î¤Ç¤¢¤ë¤¬¡¢ÊѤï¤Ã¤¿¤â¤Î¤È¤·¤Æ¤ÏÂè2¤ÈÂè22À÷¿§ÂΤΤª¤Î¤ª¤Î¤Î¾å¤Ë¤¢¤ë¦Ê¤¢¤ë¤¤¤Ï¦Ë·Úº¿¤ÎºÂÁê¸ß¤Î´Ö¤ÎžºÂ¤â¤¢¤ë¡×¡£¡Ê¥í¥Ó¥ó¥¹£ð¡¢£µ£³£¸¡Ë

¡Ê£²¡Ë

(a)
ͽ¸å¤¬ºÇ¤âÎɹ¥¤Ê¤Î¤ÏÄã´í¸±·²¤Î³Ë·¿°Û¾ï¡Êt[8;21]¡¢inv[16]¡Ë¤òȼ¤¦AML¤Ç¤¢¤ë¡£ t[8;21]¤ÏM2¡£¡¦¡¦¡¦¹ü¿ñ²êµå¤ÈÁ°¹ü¿ñµå¤¬¼çÂΤǤ¢¤ë¡£ÂçÉôʬ¤Î¾ÉÎã¤Ç¥¢¥¦¥¨¥ë¾®ÂΤ¬Â¸ºß¤¹¤ë¡£ inv[16]¤ÏM£´¡£¡¦¡¦¡¦ðùγµå¤Èñµå¤Îξ¼Ô¤Ëʬ²½¤·¡¢ðùγµå¤ÏM2¤Î¤â¤Î¤ËÎà»÷¤¹¤ë¡£Ëõ¾Ã·ìÃæ¤Îñµå¤¬Áý¿¤¹¤ë¡£
(b)
¸Ç·Á¼ðáî¤ò·ÁÀ®¤·¤ä¤¹¤¤¤Î¤Ï¡©¡Ê¤ï¤«¤ó¤Ê¤¤¡Ë M3:˦ÂÎÆâ¤Ë¿¿ô¤Î¥¢¥º¡¼¥ëðùγ¤òÍ­¤¹¤ëÁ°¹ü¿ñµå¤ÎÁý¿£¡£³Ë·¿¤ÏÉÔÀ°¤Ç¤¢¤ë¡£DIC¤ò¹âÅ٤˹çÊ»¤¹¤ë¡£ DIC¤È¤Ï¡¦¡¦¡¦¡Ö¼ï¡¹¤Î¼À´µ¤Ë¤ª¤¤¤ÆÁ´¿È¤Î¾®·ì´É¤ËÈù¾®·ìÀò¤¬À¸¤¸¤ë¾õÂÖ¤ò¸À¤¦¡£¤½¤Î¿Ê¹Ô²áÄø¤È¤Ï¡¢·ì´ÉÆâÈéºÙ˦¤Î½ý³²¤¢¤ë¤¤¤Ï·ìÀò·ÁÀ®°ø»Ò¤ÎÊü½Ð¢ªÈù¾®·ìÀò·ÁÀ®¢ª·ì¾®Èĸº¾¯¤È¶Å¸Ç°ø»Ò¤Î¾ÃÈñ¢ªÀþ°ÝÁÇÍϲòµ¡¹½¤¬Ð¶¿Ê¢ª½Ð·ì·¹¸þ¡Ê¾ÃÈñÀ­¶Å¸Ç½ý³²consumption coagulopathy¡Ë¤¬¸«¤é¤ì¤ë¡£°ìÊý¤Ç¤Ï·ìÀò·ÁÀ®¤Î¤¿¤á¡´ï¤Îµõ·ì¡¢¹´Â«¤ò°ú¤­µ¯¤³¤¹¡£¡×
¡Ê£ã¡Ë
M3 acute promyelocytic leukemia µÞÀ­Á°¹ü¿ñÀ­Çò·ìÉ ²òÀ⡦¡¦¡¦ðùγµå¤Îʬ²½¤Ë¤Ä¤¤¤Æ¡£

1.¡¡ßÉ˦À­¥ê¥ó¥Ñ¼ð¤Ë¤Ä¤¤¤Æ¡¢¸÷¸²¥ì¥Ù¥ë¤Ç¤Î·ÁÂÖ³ØŪÀ­¾õ¡¦ÌȱֳØŪɽ¸½·¿¡¦À÷¿§Âΰ۾°äÅÁ»Ò°Û¾ï¤Î4ÅÀ¤ò¡¢Â¾¤Î°¡·¿¤È¤Ï°Û¤Ê¤ëÆÃħŪ¤Ê»ö¹à¤òµ­¤·¤Ê¤µ¤¤¡£
¡Ê£²£°£°£³Ç¯ÉÂÍý³ØÃæ´Ö»î¸³£±¡Ë

²òÅú¡§

·ÁÂÖ³ØŪÆÃħ
¥ê¥ó¥ÑÀá¤Ï¡¢¼å³ÈÂç¤Ç¤â¤Ï¤Ã¤­¤ê¤ï¤«¤ë·ëÀá¾õ³°´Ñ¤òÄ褷¤ÆÁý¿£¤¹¤ë¼ðáçºÙ˦¤Ë¤è¤Ã¤ÆÃÖ´¹¤µ¤ì¤Æ¤¤¤ë¡£Â¿¤¯¤Î¾ì¹ç¡¢¼ðáçºÙ˦¤Ï¤Û¤È¤ó¤ÉcentrocyteÍͺÙ˦¤Ç¤¢¤ë¡£CentrocyteÍͺÙ˦¤Ï¡¢ÀÚ¤ì¹þ¤ß¤Î¤¢¤ë³ÑÄ¥¤Ã¤¿³Ë¤ÎÎسԤò¼¨¤·¡¢³Ë¥¯¥í¥Þ¥Á¥ó¤ÏÁÆÂç¤ÇÇ»½Ì¤·¤Æ¤ª¤ê¡¢³Ë¾®ÂΤÏÉÔÌÀÎƤǤ¢¤ë¡£

Centrocyte¤Ï¡¢¤â¤Ã¤ÈÂç·¿¤ÇµÙ»ß´ü¤Î¥ê¥ó¥Ñµå¤Î£³¡Á£´ÇܤÎÂ礭¤µ¤ò»ý¤Ä¡¢centroblastÍͺÙ˦¤È¤¤¤í¤¤¤í¤ÊÈæΨ¤Çº®ºß¤·¤Æ¤¤¤ë¡£Centrocyte¤Ï¡¢³Ë¥¯¥í¥Þ¥Á¥ó¤Ï¾®Ë¦¾õ¤Ç¿ô¸Ä¤Î³Ë¾®ÂΤò¤â¤Á¡¢Àµ¾ï¤ÊæõÃæ¿´¤Ëǧ¤á¤é¤ì¤ëʬÎö³èÀ­¤Î¹â¤¤ºÙ˦¤ËÎà»÷¤·¤Æ¤¤¤ë¡£

ÌȱֳØŪɽ¸½·¿
æõÃæ¿´ºÙ˦µ¯¸»¤Î¼ðáç¤Ç¤¢¤ë¤¿¤á¡¢¤³¤ì¤é¤Î¼ðáçºÙ˦¤Ë¤ÏCD£±£¹¤äCD£²£°¤Î¤è¤¦¤ÊÈÆBºÙ˦À­¥Þ¡¼¥«¡¼¤¬ÍÛÀ­¤Ç¤¢¤ê¡¢¤Þ¤¿Â¿¤¯¤Î¾ÉÎã¤Ç¤Ï¤µ¤é¤ËBºÙ˦À­¤Î°ìÉô¤Ë¸ÂÄꤵ¤ì¤¿¥Þ¡¼¥«¡¼¤Ç¤¢¤ëCD£±£°¤¬ÍÛÀ­¤È¤Ê¤ë¡£²Ã¤¨¤Æ¡¢¼ðáçºÙ˦¤Ç¤ÏBCL£²ÃÁÇò¼Á¤òȯ¸½¤·¤Æ¤ª¤ê¡¢BCL£²±¢À­¤ÎÀµ¾ï¤ÊæõÃæ¿´BºÙ˦¤È¤Î´ÕÊ̾塢½ÅÍפÊÆÃĹ¤È¤Ê¤Ã¤Æ¤¤¤ë¡£
À÷¿§Âΰ۾ï
£ô(14¡¨18)¤¹¤Ê¤ï¤Á£±£´ÈÖÀ÷¿§ÂΤȣ±£¸ÈÖÀ÷¿§ÂΤΞºÂ¤¬¤¢¤ë¡££±£¸ÈÖÀ÷¿§ÂΤÎÀÚÃÇÅÀ¤Ï18q21¤ò´Þ¤ó¤Ç¤ª¤ê¡¢Æ±Éô¤Ë¤Ï¥¢¥Ý¥È¡¼¥·¥¹ÍÞÀ©°äÅÁ»ÒBCL£²¤¬Â¸ºß¤¹¤ë¡£¤³¤ÎžºÂ¤ÏBCL£²ÃÁÇò¼Á¤Î²á¾êȯ¸½¤ò°ú¤­µ¯¤³¤¹¡£

11.¡¡µÞÀ­Çò·ìɤÎFABʬÎà¤Ë¤ª¤±¤ëM2¡ÊWHO¡§AML with maturation¡Ë¡¢ M3¡ÊWHO¡§acute promyelocytic leukemia¡Ë¤Î¼ðáçºÙ˦¤Ë¤Ä¤¤¤Æ¡¢¤½¤ì¤¾¤ì¤Î·ÁÂÖ³ØŪÆÃħ¤ò½Ò¤Ù¡¢¸å¼Ô¤Ë¤Ä¤¤¤Æ¤Ï¤½¤ÎÀ÷¿§Âΰ۾ï¤ÎÍͼ°¤âµ­¤»¡¥
¡Ê£²£°£°£³Ç¯ÉÂÍý³ØºÆ»î¸³£±£±¡Ë

²òÅú¡¦¡¦¡¦

M0¡§¤´¤¯¤ï¤º¤«¤Ëʬ²½¤·¤¿µÞÀ­¹ü¿ñÀ­Çò·ìÉÂ
M1¡§Ê¬²½·¹¸þ¤Î¤Ê¤¤µÞÀ­¹ü¿ñÀ­Çò·ìÉÂ
Èó¾ï¤ËÍļå¤Ê¹ü²êµå¼çÂΤǾ¯¿ô¤Îðùγ¤¢¤ë¤¤¤Ï¥¢¥¦¥¨¥ë¾®ÂΤ¬Â¸ºß¤¹¤ë¡£PhÀ÷¿§ÂΤ¬£±£°¡Á£±£µ¡ó¸ºß¤¹¤ë¾©Îå¤Ïͽ¸åÉÔÎɤǤ¢¤ë¡£
M2¡§Acute myeloid leukemia with maturation
¹ü¿ñ²êµå¤¬£³£°¡ó°Ê¾å¤Ç¡¢Á°¹ü¿ñµå°Ê¹ß¤Îðùγµå·ÏºÙ˦¤¬£±£°¡ó°Ê¾å¤Ç¤¢¤ë¡£À÷¿§Âΰ۾ï¤ÎÍͼ°¤Ï£ô¡Ê£¸¡§£²£±¡Ë¡£¡Ê¥×¥ê¥ó¥È¤«¤é¡Ë ÂçÉôʬ¤Î¾ÉÎã¤Ç¥¢¥¦¥¨¥ë¾®ÂΤ¬Â¸ºß¤¹¤ë¡£
M3 : Acute promyelocytic leukemia
˦ÂÎÆâ¤Ë¿¿ô¤Î¥¢¥º¡¼¥ëðùγ¤òÍ­¤¹¤ëÁ°¹ü¿ñµå¤ÎÁý¿£¤Ç¡¢³Ë·¿¤¬ÉÔÀ°¤Ç¤¢¤ë¡£DIC¤ò¹âÅ٤˹çÊ»¤·¡¢À÷¿§Âΰ۾ï¤ÎÍͼ°¤Ï£ô¡Ê£±£µ¡¨£±£·¡Ë¡£¡Ê¥×¥ê¥ó¥È¤«¤é¡Ë¤·¤Ð¤·¤Ð¿¿ô¤Î¥¢¥¦¥¨¥ë¾®ÂΤ¢¤ê¡£¿Õ·Á¤¢¤ë¤¤¤ÏÆóʬÍÕ¾õ¤Î³Ë·¿¤ò¼¨¤¹¡£
M4:µÞÀ­¹ü¿ññµåÀ­Çò·ìÉ¡¡
ðùγµå¤Èñµå¤Îξ¼Ô¤Ëʬ²½¤¹¤ë¡£ðùγµå¤ÏM2¤Î¤â¤Î¤ËÎà»÷¤·¡¢Ëõ¾Ã·ìÃæ¤Îñµå¤¬Áý²Ã¤¹¤ë¡£ µÕ°Ì£±£¶¤¢¤ë¤¤¤Ï£±£¶£ñ·ç¼º¤Î¸ºß¤Ïͽ¸åÎɹ¥¤Ç¤¢¤ë¡£
M5:µÞÀ­Ã±µåÀ­Çò·ìÉÂ
¡¡Ã±²êµå¡Ê¥Ú¥ë¥ª¥­¥·¥À¡¼¥¼±¢À­¡¢¥¨¥¹¥Æ¥é¡¼¥¼ÍÛÀ­¡Ë¤ÈÁ°Ã±µå¤¬¼çÂΤǤ¢¤ë¡£Ä̾ï»Ò¶¡¤ä¼ãǯ¼Ô¤Ëȯ¾É¤·¡¢°ìÈ̤˻õÆù¿»½á¤¬¸«¤é¤ì¡¢À÷¿§ÂÎ11q23¤Î¸ºß¤Ïͽ¸åÉÔÎɤǤ¢¤ë¡£
M6:µÞÀ­ÀÖÇò·ìÉÂ
M7:µÞÀ­µð³ËµåÀ­Çò·ìÉÂ

7. A¡ËState histological and phenotypical characterization of Hodgkin lymphoma emphasizing those characteristics which are different from "non-Hodgkin lymphoma" (answer in Japanese).

B¡ËState one representative detailed subtype of leukemia or lymphoma which is highly associated with each cytogenetic abnormality in (1) to (5).

(1) t(9;22)(q34;q11)
(2) t(14;18)(q32;q21)
(3)(11;14)(q13;q32)
(4) t(8;14)(q24;q32)
(5) t(15;17)(q22;q21)
¡Ê£²£°£°£²Ç¯ÉÂÍý³ØÃæ´Ö»î¸³¡¡£·¡Ë

²òÅú A) ¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¤ÎÁÈ¿¥³ØŪ¡¢ÌȱֳØŪɽ¸½·¿¤ÎÆÃħ¤ò¡¢Èó¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¤È¤Î°ã¤¤¤ò¶¯Ä´¤·¤Æ½Ò¤Ù¤è¡£

ÉÂÂ֤ΰ㤤¡£
¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ðÈó¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð
ñ°ì¥ê¥ó¥ÑÀá·²¤Ë¸Â¶ÉÊ£¿ô¤ÎËõ¾¿¥ê¥ó¥ÑÀáÆâ¤Ë¿»½á¤¹¤ë¡£
Ä̾ïϢ³Ū¤Ë¿ÊŸÈóϢ³Ū¤Ë¿ÊŸ
IJ´ÖËì¥ê¥ó¥ÑÀá¤äWal-deyerÎؤ¬¿¯¤µ¤ì¤ë¤³¤È¤Ï¤Þ¤ì¡£WaldeyerÎؤäIJ´ÖËì¥ê¥ó¥ÑÀ᤬¿¯¤µ¤ì¤ë¡£
Àá³°À­¿»½á¤Ï¤Þ¤ì¡£Àá³°À­¿»½á¤â¤¹¤ë¡£
ÁÈ¿¥³ØŪÆÃħ¤Î°ã¤¤¡£
RSºÙ˦¤¬Â¸ºß¤¹¤ë¡£RSºÙ˦¤È¤Ï¡¢
  1. Ë­¤«¤ÊÄ̾ï¼å¹¥»ÀÀ­¤ÎºÙ˦¼Á¤òÍ­¤¹¤ë¡£
  2. ¤¤¤¯¤Ä¤Ë¤âʬÍÕ¤·¤¿³Ë¤¢¤ë¤¤¤Ï¿³Ë¤ò»ý¤Á¡¢Âç·¿¡¢±ß·Á¤Î³Ë¾®ÂΤòÍ­¤·¤Æ¤¤¤ë¡£
  3. 2¤Ä¤Î³Ë¤¬¶ÀÁü¤Î¤è¤¦¤Ë¸ºß¤¹¤ë¡£
  4. ¤ª¤Î¤ª¤Î¤¬Âç·¿¡ÊÉõÆþÂÎÍ͡ˤι¥»ÀÀ­³Ë¾®ÂΤǤ¢¤ë¡£
  5. ÆÈÆäÊÌÀÚô(halo)¤Ç°Ï¤Þ¤ì¤Æ¤¤¤ë¡£
  6. ¤½¤ì¤é¤¬¤Õ¤¯¤í¤¦¤ÎÌܤΤ褦¤Ë¸«¤¨¤ë¡£
  7. ³ËËì¤ÏÌÀÎƤǤ¢¤ë¡£ ¡¡
ÌȱֳØŪɽ¸½·¿¤Î°ã¤¤¡£
¤ï¤«¤é¤ó¡£¤«¤¤¤Æ¤Ê¤¤¡£

B) °Ê²¼¤Î£±¡Á£µ¤Ë¤Ä¤¤¤Æ¡¢ºÙ˦¼Á°äÅÁ»Ò¤Î°Û¾ï¤Ë¶¯¤¯´ØÏ¢¤¹¤ë¡¢ÂåɽŪ¤ÊÇò·ìɤޤ¿¤Ï¥ê¥ó¥Ñ¼ð¤ò½Ò¤Ù¤è¡£

£±¡¢ËýÀ­¹ü¿ñÀ­Çò·ìÉÂ
¥í¥Ó¥ó¥¹P¡¢£µ£µ£°¡¡Á°¤Ë½ñ¤¤¤¿¡£
£²¡¢ßÉ˦À­¥ê¥ó¥Ñ¼ð
¥ê¥ó¥ÑÀá¤Ï¡¢¼å³ÈÂç¤Ç¤â¤Ï¤Ã¤­¤ê¤ï¤«¤ë·ëÀá¾õ³°´Ñ¤òÄ褷¤ÆÁý¿£¤¹¤ë¼ðáçºÙ˦¤Ë¤è¤Ã¤ÆÃÖ´¹¤µ¤ì¤Æ¤¤¤ë¡£Â¿¤¯¤Î¾ì¹ç¡¢¼ðáçºÙ˦¤Ï¤Û¤È¤ó¤ÉcentrocyteÍͺÙ˦¤Ç¤¢¤ë¡£~CentrocyteÍͺÙ˦¤Ï¡¢ÀÚ¤ì¹þ¤ß¤Î¤¢¤ë³ÑÄ¥¤Ã¤¿³Ë¤ÎÎسԤò¼¨¤·¡¢³Ë¥¯¥í¥Þ¥Á¥ó¤ÏÁÆÂç¤ÇÇ»½Ì¤·¤Æ¤ª¤ê¡¢³Ë¾®ÂΤÏÉÔÌÀÎƤǤ¢¤ë¡£
Centrocyte¤Ï¡¢¤â¤Ã¤ÈÂç·¿¤ÇµÙ»ß´ü¤Î¥ê¥ó¥Ñµå¤Î£³¡Á£´ÇܤÎÂ礭¤µ¤ò»ý¤Ä¡¢centroblastÍͺÙ˦¤È¤¤¤í¤¤¤í¤ÊÈæΨ¤Çº®ºß¤·¤Æ¤¤¤ë¡£Centrocyte¤Ï¡¢³Ë¥¯¥í¥Þ¥Á¥ó¤Ï¾®Ë¦¾õ¤Ç¿ô¸Ä¤Î³Ë¾®ÂΤò¤â¤Á¡¢Àµ¾ï¤ÊæõÃæ¿´¤Ëǧ¤á¤é¤ì¤ëʬÎö³èÀ­¤Î¹â¤¤ºÙ˦¤ËÎà»÷¤·¤Æ¤¤¤ë¡£ ¥í¥Ó¥ó¥¹P¡¢£µ£³£µ
£³¡¢¥Þ¥ó¥È¥ëºÙ˦¥ê¥ó¥Ñ¼ð
ÁÈ¿¥³ØŪÆÃħ
¡¡¼ðáçºÙ˦¤ÏÀµ¾ï¤Î¥ê¥ó¥Ñµå¤è¤ê¤â¤ä¤äÂ礭¤¯¡¢³Ë¤ÏÉÔµ¬Â§¤ÊÀÚ¤ì¹þ¤ß¤ò¼¨¤·¡¢³Ë¾®ÂΤÏÉÔÌÀÎƤǤ¢¤ë¡£¹ü¿ñ¿»½á¤¬¤¢¤ê¡¢£²£°¡ó¤Î¾ÉÎã¤Ïȯ¸«»þ¤ËÇò·ì²½¤·¤Æ¤¤¤ë¡£ÆÃħŪ¤Ê·¹¸þ¤È¤·¤Æ¡¢¾Ã²½´É¤Ë¤·¤Ð¤·¤Ð¿»½á¤¹¤ë¤³¤È¤¬¤¢¤ê¡¢»þ¤Ë¤ÏÆù´ãŪ¤Ë¥Ý¥ê¡¼¥×¤Ë»÷¤¿Â¿ÁãÀ­¤ÎÇ´Ëì²¼·ëÀá¡Ê¥ê¥ó¥Ñ¼ðÍͥݥ꡼¥×lymphomatoid¡¡polyposis¡Ë¤Î·Á¤ò¼è¤ë¡£
ÌȱֳØŪÆÃħ
¡¡¼ðáçºÙ˦¤ÏÄ̾ºÙ˦ɽÌ̤ËIgM¤ÈIgD¡¢ÈÆBºÙ˦¹³¸¶¤ÎCD19¡¢CD£²£°¡¢CD£²£²¤ª¤è¤Ó¡ÊCLL¡¿SLL¤Î¤è¤¦¤Ë¡ËCD£µ¤ò¶¦È¯¸½¤·¤Æ¤¤¤ë¡£¥Þ¥ó¥È¥ëºÙ˦¥ê¥ó¥Ñ¼ð¤Ï¡¢Áý¿£Ãæ¿´¤«¤é·çÇ¡¤¹¤ë¤³¤È¤ÈcyclinD1ÃÁÇò¼Á¤Î°Û¾ï¤Ê¹âȯ¸½¤Î¸ºß¤Ë¤è¤Ã¤ÆCLL¡¿SLL¤È¶èÊ̤¹¤ë¡£ ¥í¥Ó¥ó¥¹P¡¢£µ£³£¶
£´¡¢¥Ð¡¼¥­¥Ã¥È¥ê¥ó¥Ñ¼ð
¥í¥Ó¥ó¥¹P¡¢£µ£³£¸
ÁÈ¿¥³ØŪɽ¸½·¿
¼ðáçºÙ˦¤ÏñĴ¤Ç¡¢¤½¤ÎÂ礭¤µ¤Ï¾®¥ê¥ó¥Ñµå¤ÈÂç·¿ÈóÀÚ¤ì¹þ¤ß³Ë¤ò»ý¤Ã¤¿ºÙ˦¤È¤ÎÃæ´Ö¤Ç¤¢¤ë¡£³Ë¤Ï±ß·Á¤¢¤ë¤¤¤ÏÍñ±ß·Á¤Ç¤¢¤ê¡¢£²¡Á£µ¸Ä¤ÎÌÀÎƤʳ˾®ÂΤòÍ­¤¹¤ë¡£ºÙ˦ʬÎö»Ø¿ô¤¬¹â¤¤¤³¤È¤¬¡¢¤³¤Î¼ðáç¤ÎÂ礭¤ÊÆÃħ¤Ç¤¢¤ê¡¢»àÌǺÙ˦¤â¿¤¤¤Î¤Ç¡¢³ËÊÒ¤òìÅ¿©¤·¤¿¥Þ¥¯¥í¥Õ¥¡¡¼¥¸¤¬Â¿¿ôǧ¤á¤é¤ì¤ë¡£
ÌȱֳØŪɽ¸½·¿
¡¡Ëܼðáç¤ÏBºÙ˦À­¤Ç¤¢¤ê¡¢ºÙ˦ɽÌ̤ÏIgM¡¢CD19¤Î¤è¤¦¤ÊÈÆBºÙ˦À­¥Þ¡¼¥«¡¼¡¢¤Þ¤¿CD£±£°¹³¸¶¤¬ÍÛÀ­¤Ç¤¢¤ë¡£
£µ¡¢µÞÀ­Çò·ìÉ¡¡M£³¡£
¥í¥Ó¥ó¥¹P¡¢£µ£´£¹¡¥ Acute promyelocytic leukemia ˦ÂÎÆâ¤Ë¿¿ô¤Î¥¢¥º¡¼¥ëðùγ¤òÍ­¤¹¤ëÁ°¹ü¿ñµå¤ÎÁý¿£¤¬¸«¤é¤ì¡¢³Ë·¿¤ÏÉÔÀ°¤Ç¤¢¤ë¡£

3.¡¡Answer the followings.
1) The patient, 56 year old male, was found to have a monoclonal hyperganmmaglobulinemia (IgG/kappa type) and Bence-Jones protein in urea. This microphotograph shows the histology of the patient¡Çs bone marrow.

In English or Japanese,
(A) describe at least two cytological features in the neoplastic cells and
(B) provide a diagnosis of the patient.

2) Select one and only one disease/subtype from those listed in (a) - (j) and match it with the feature listed in (1)-(10), with which it is most associated.

(a) myelofibrosis 
(b) follicular lymphoma 
(c) chronic myelogenous leukemia (CML) 
(d) acute myeloid leukemia 
(e) sarcoidosis 
(f) mantle cell lymphoma 
(g) Burkitt lymphoma 
(h) thymomas 
(i) myelodysplastic syndrome(MDS) 
(j) Hodgkin lymphoma 
(1) t(9;22)(q34;q11) 
(2) t(14;18)(q32;q21) 
(3) t(11;14)(q13;q32) 
(4) t(8;14)(q24;q32) 
(5) extramedullary hematopoiesis 
(6) 5q- cytogenetic abnormality 
(7) asteroid body in multinucleated giant cell 
(8) single cell PCR analysis using CD30+ cells 
(9) Auer body (Auer rod) 
(10) CD4+CD8+ immature/precursor T lymphocyte

¡Ê2001ǯÉÂÍý³Ø´üËö»î¸³£³¡Ë

²òÅú £±¡¢Bence¡ÝJones protein¤Ï·Á¼ÁºÙ˦¼ð¤Ë¤è¤Ã¤Æ»ºÀ¸¤µ¤ì¤ë°Û¾ï¤ÊÃÁÇò¤Ç¤¢¤ë¡£¤½¤Î¤¿¤á¡¢¼ðáçºÙ˦¤Ï°Ê²¼¤ÎÆÃħ¤¬µó¤²¤é¤ì¤ë

  • ¼Ö¼´¾õ¤Î*1³Ë¤ò»ý¤Ã¤¿·Á¼ÁºÙ˦¤¬Â¿¤¯¸«¤é¤ì¤ë
  • °Û¾ï¤ÊÌȱ֥°¥í¥Ö¥ê¥ó¤ò»ºÀ¸¤¹¤ë

£²¡¢(a)5 (b)2 (c)1 (d)9 (e)8 (f)3 (g)4 (h)10 (i)6 (j)7

»î¸³ÌäÂê

1ǯÀ¸

2ǯÀ¸

3ǯÀ¸

4ǯÀ¸

6ǯÀ¸

¶¦Íѻ

¥ê¥ó¥¯½¸

ºÇ¿·¤Î20·ï

2022-09-06 2021-01-31 2021-01-06 2016-11-16 2016-11-14 2016-11-11 2016-11-09 2014-07-27 2014-01-30 2013-01-12 2012-05-15 2010-10-04 2010-07-18 2010-07-04 2009-09-21 2009-03-01 2009-01-23

¥á¥Ë¥å¡¼¥Ð¡¼¤ÎÊÔ½¸

  • counter: 2140
  • today: 1
  • yesterday: 0
  • online: 1


*1 ÁÈ¿¥³Ø¤Ç¥«¥Ë¶µ¼ø¤¬¡Ö¥¨¥­¥»¥ó¥È¥ê¥Ã¥¯¤À¡×¤È¸À¤Ã¤¿ºÙ˦¤Ç¤¹¤è